Angioedema
MONDO:0010481Swelling involving the deep dermis, subcutaneous, or submucosal tissues, representing localized edema. Angioedema often occurs in the face, lips, tongue, and larynx.
Also known as: Edemas, angioneurotic, Quincke edema, Quincke oedema, Quincke's edema, Quincke's oedema, Quinckes edema, Quinckes oedema, Urticarias, giant
67 clinical trials for this condition and its sub-types, 19 tagged with Angioedema itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Angioedema
-
Hereditary angioedema 58 trials · 60 incl. sub-types
10 sub-types
- Hereditary angioedema with C1Inh deficiency 14 trials · 32 incl. sub-types Sub-types →
- Hereditary angioedema type 3 2 trials
- Hereditary angioedema with normal C1Inh 2 trials
- PLG-related hereditary angioedema with normal C1inh 0 trials
- Angioedema, hereditary, 4 0 trials
- Angioedema, hereditary, 5 0 trials
- Angioedema, hereditary, 6 0 trials
- Angioedema, hereditary, 7 0 trials
- Angioedema, hereditary, 8 0 trials
- Hereditary angioedema with normal C1inh not related to F12 or PLG variant 0 trials
-
Acquired angioedema 2 trials · 3 incl. sub-types
5 sub-types
- Renin-angiotensin-aldosterone system-blocker-induced angioedema 2 trials
- Acquired angioedema with C1Inh deficiency 1 trial
- Acquired angioedema type 1 0 trials
- Acquired angioedema type 2 0 trials
- Vibratory angioedema 0 trials
-
Non-histaminic angioedema 2 trials
Most studied deeper sub-types
-
New drug navenibart aims to tame hereditary swelling attacks
Disease control CompletedThis early trial tested a new drug called navenibart in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received one or two doses of the drug to check its safety and how well it might reduce attacks. The study is …
Phase 1/2 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New pill could tame stubborn hives when antihistamines fail
Disease control CompletedThis phase 2 trial tested an oral drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching lasting months) that standard antihistamines couldn't control. Participants took either povorcitinib or a placebo for 12 weeks to see if the drug reduced…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New tablet shows promise for chronic hives in small study
Symptom relief CompletedThis study tested a daily tablet called NatureU Histra Disslove in 19 adults with chronic hives. Participants took one tablet before a main meal for 28 days. The study measured how well the tablet controlled hives, reduced symptoms, and improved quality of life. Results showed ch…
Sponsor: OmniSolutions Laboratory Holdings Limited • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
ER hives study: do steroids really help?
Symptom relief CompletedThis study tested whether giving a steroid (cortancyl) along with an antihistamine (levocetirizine) is better than the antihistamine alone for treating sudden hives in the emergency department. 137 adults with acute urticaria (with or without mild angioedema) were enrolled. The m…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC